{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:44:22Z","timestamp":1792683862220,"version":"4.5.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T00:00:00Z","timestamp":1679443200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.phrs.2023.106742","type":"journal-article","created":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T13:24:58Z","timestamp":1679491498000},"page":"106742","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["Late relapse after CAR-T cell therapy for adult patients with hematologic malignancies: A definite evidence from systematic review and meta-analysis on individual data"],"prefix":"10.1016","volume":"190","author":[{"given":"Alessia","family":"Zinzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Gaio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerio","family":"Liguori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Cagnotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donatella","family":"Paolino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Paolisso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Castaldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni Francesco","family":"Nicoletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Capuano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concetta","family":"Rafaniello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2023.106742_bib1","doi-asserted-by":"crossref","first-page":"105930","DOI":"10.1016\/j.phrs.2021.105930","article-title":"The role of MOZ\/KAT6A in hematological malignancies and advances in MOZ\/KAT6A inhibitors","volume":"174","author":"Su","year":"2021","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.phrs.2023.106742_bib2","doi-asserted-by":"crossref","unstructured":"Motais, B.; Charv\u00e1tov\u00e1, S.; Hrdinka, M.; \u0160im\u00ed\u010dek, M.; Jel\u00ednek, T.; \u0160ev\u010d\u00edkov\u00e1, T.; Ko\u0159\u00edstek, Z.; H\u00e1jek, R.; Bag\u00f3, J.R. A Bird\u2019s-Eye View of Cell Sources for Cell-Based Therapies in Blood Cancers. Cancers (Basel). 2020, 12, doi:10.3390\/cancers12051333.","DOI":"10.3390\/cancers12051333"},{"key":"10.1016\/j.phrs.2023.106742_bib3","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1634\/theoncologist.2015-0421","article-title":"Chimeric antigen receptor T-Cell therapy for the community oncologist","volume":"21","author":"Maus","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.phrs.2023.106742_bib4","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.phrs.2023.106742_bib5","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1186\/s13287-021-02595-0","article-title":"CAR-T cell therapy in T-cell malignancies: Is success a low-hanging fruit?","volume":"12","author":"Safarzadeh Kozani","year":"2021","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.phrs.2023.106742_bib6","doi-asserted-by":"crossref","unstructured":"Food and Drug Administration TECARTUS (brexucabtagene autoleucel) Available online: https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/tecartus-brexucabtagene-autoleucel (accessed on Dec 1, 2022).","DOI":"10.51731\/cjht.2021.135"},{"key":"10.1016\/j.phrs.2023.106742_bib7","unstructured":"Food and Drug Administration KYMRIAH (tisagenlecleucel) Available online: https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/kymriah-tisagenlecleucel (Accessed on 1 December 2022)."},{"key":"10.1016\/j.phrs.2023.106742_bib8","unstructured":"Food and Drug Administration YESCARTA (axicabtagene ciloleucel) Available online: https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/yescarta-axicabtagene-ciloleucel (Accessed on 1 December 2022)."},{"key":"10.1016\/j.phrs.2023.106742_bib9","unstructured":"Food and Drug Administration BREYANZI (lisocabtagene maraleucel) Available online: https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/breyanzi-lisocabtagene-maraleucel (Accessed on 1 December 2022)."},{"key":"10.1016\/j.phrs.2023.106742_bib10","doi-asserted-by":"crossref","unstructured":"Food and Drug Administration ABECMA (idecabtagene vicleucel) Available online: https:\/\/www.fda.gov\/vaccines-blood-biologics\/abecma-idecabtagene-vicleucel (Accessed on 1 December 2022).","DOI":"10.51731\/cjht.2021.198"},{"key":"10.1016\/j.phrs.2023.106742_bib11","unstructured":"Food and Drug Administration CARVYKTI Available online: https:\/\/www.fda.gov\/vaccines-blood-biologics\/carvykti (accessed on Dec 1, 2022)."},{"key":"10.1016\/j.phrs.2023.106742_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.exphem.2022.02.001","article-title":"Challenges of chimeric antigen receptor T-cell therapy in chronic lymphocytic leukemia: lessons learned","volume":"108","author":"Can","year":"2022","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.phrs.2023.106742_bib13","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.phrs.2017.11.035","article-title":"CAR-T cells and combination therapies: What\u2019s next in the immunotherapy revolution?","volume":"129","author":"Ramello","year":"2018","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.phrs.2023.106742_bib14","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-Cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.phrs.2023.106742_bib15","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.phrs.2023.106742_bib16","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1631\/jzus.B2200256","article-title":"Relapse after CAR-T cell therapy in B-cell malignancies: challenges and future approaches","volume":"23","author":"Gu","year":"2022","journal-title":"J. Zhejiang Univ. Sci. B"},{"key":"10.1016\/j.phrs.2023.106742_bib17","article-title":"Clinical determinants of relapse following CAR-T therapy for hematologic malignancies: coupling active strategies to overcome therapeutic limitations","volume":"70","author":"Wang","year":"2022","journal-title":"Curr. Res. Transl. Med."},{"key":"10.1016\/j.phrs.2023.106742_bib18","first-page":"10","article-title":"Efficacy of second CAR-T (CART2) infusion limited by poor CART expansion and antigen modulation","author":"Holland","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.phrs.2023.106742_bib19","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"10","author":"Page","year":"2021","journal-title":"Syst. Rev."},{"key":"10.1016\/j.phrs.2023.106742_bib20","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s10549-012-2395-8","article-title":"Comparing duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial: application of new methodology","volume":"138","author":"Garnett","year":"2013","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.phrs.2023.106742_bib21","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s12874-021-01381-z","article-title":"Conducting proportional meta-analysis in different types of systematic reviews: a guide for synthesisers of evidence","volume":"21","author":"Barker","year":"2021","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.phrs.2023.106742_bib22","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1136\/jech-2013-203104","article-title":"Meta-analysis of prevalence","volume":"67","author":"Barendregt","year":"2013","journal-title":"J. Epidemiol. Community Health"},{"key":"10.1016\/j.phrs.2023.106742_bib23","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet (Lond., Engl. )"},{"key":"10.1016\/j.phrs.2023.106742_bib24","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1182\/bloodadvances.2019000151","article-title":"Tisagenlecleucel in relapsed\/refractory diffuse large B-cell lymphoma patients without measurable disease at infusion","volume":"3","author":"Bishop","year":"2019","journal-title":"Blood Adv."},{"key":"10.1016\/j.phrs.2023.106742_bib25","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1200\/JCO.20.01467","article-title":"Long-term follow-up of anti-CD19 chimeric antigen receptor T-cell therapy","volume":"38","author":"Cappell","year":"2020","journal-title":"J. Clin. Oncol. . J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.phrs.2023.106742_bib26","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial","volume":"28","author":"Fowler","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.phrs.2023.106742_bib27","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.phrs.2023.106742_bib28","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/s41591-022-01731-4","article-title":"Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial","volume":"28","author":"Neelapu","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.phrs.2023.106742_bib29","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1182\/bloodadvances.2020003092","article-title":"Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma","volume":"4","author":"Pasquini","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.phrs.2023.106742_bib30","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","article-title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Schuster","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.phrs.2023.106742_bib31","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jaci.2020.07.025","article-title":"Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies","volume":"146","author":"Freyer","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.phrs.2023.106742_bib32","first-page":"28","article-title":"Axicabtagene ciloleucel (axi-cel; KTE-C19) in patients with refractory aggressive non-Hodgkin lymphomas (NHL): primary results of the pivotal trial ZUMA-1","volume":"35","author":"Neelapu","year":"2017","journal-title":"Hematol. Oncol. Conf. 14th Int. Conf. Malig. Lymphoma Palazzo dei Congr. Switz."},{"key":"10.1016\/j.phrs.2023.106742_bib33","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-Cell lymphoma: results from the US lymphoma CAR T consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J. Clin. Oncol. . J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.phrs.2023.106742_bib34","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2021015209","article-title":"GLA\/DRST real-world outcome analysis of CAR-T cell therapies for large B-cell lymphoma in Germany","author":"Bethge","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2023.106742_bib35","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1002\/cam4.3881","article-title":"Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma","volume":"10","author":"Iacoboni","year":"2021","journal-title":"Cancer Med"},{"key":"10.1016\/j.phrs.2023.106742_bib36","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1182\/blood.2022016945","article-title":"Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis","volume":"140","author":"Di Blasi","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2023.106742_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2021.112971","article-title":"Resistance and recurrence of malignancies after CAR-T cell therapy","volume":"410","author":"Zeng","year":"2022","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.phrs.2023.106742_bib38","doi-asserted-by":"crossref","first-page":"106036","DOI":"10.1016\/j.phrs.2021.106036","article-title":"Improving the ability of CAR-T cells to hit solid tumors: Challenges and strategies","volume":"175","author":"Zhang","year":"2022","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.phrs.2023.106742_bib39","doi-asserted-by":"crossref","first-page":"106454","DOI":"10.1016\/j.phrs.2022.106454","article-title":"Nanotechnology-based chimeric antigen receptor T-cell therapy in treating solid tumor","volume":"184","author":"Zuo","year":"2022","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.phrs.2023.106742_bib40","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1186\/s12967-022-03442-3","article-title":"Exhaustion of CAR T cells: potential causes and solutions","volume":"20","author":"Kouro","year":"2022","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.phrs.2023.106742_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.904497","article-title":"CAR T-cell therapy predictive response markers in diffuse large B-Cell lymphoma and therapeutic options after CART19 failure","volume":"13","author":"Caballero","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.phrs.2023.106742_bib42","doi-asserted-by":"crossref","unstructured":"Lechermann, L.M.; Lau, D.; Attili, B.; Aloj, L.; Gallagher, F.A. In Vivo Cell Tracking Using PET: Opportunities and Challenges for Clinical Translation in Oncology. Cancers (Basel). 2021, 13, doi:10.3390\/cancers13164042.","DOI":"10.3390\/cancers13164042"},{"key":"10.1016\/j.phrs.2023.106742_bib43","doi-asserted-by":"crossref","DOI":"10.1007\/s00432-023-04587-4","article-title":"Prognostic value of baseline and early response FDG-PET\/CT in patients with refractory and relapsed aggressive B-cell lymphoma undergoing CAR-T cell therapy","author":"Georgi","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.phrs.2023.106742_bib44","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1158\/1078-0432.CCR-20-2770","article-title":"Molecular imaging of chimeric antigen receptor T Cells by ICOS-immunoPET","volume":"27","author":"Simonetta","year":"2021","journal-title":"Clin. Cancer Res. . J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.phrs.2023.106742_bib45","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1158\/1078-0432.CCR-19-3888","article-title":"Dissecting the tumor-immune landscape in chimeric antigen receptor T-cell therapy: key challenges and opportunities for a systems immunology approach","volume":"26","author":"Chen","year":"2020","journal-title":"Clin. Cancer Res. . J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.phrs.2023.106742_bib46","doi-asserted-by":"crossref","first-page":"5827","DOI":"10.1002\/jcp.27519","article-title":"Predictive and therapeutic biomarkers in chimeric antigen receptor T-cell therapy: a clinical perspective","volume":"234","author":"Mirzaei","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.phrs.2023.106742_bib47","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.3389\/fimmu.2020.01217","article-title":"Next-generation manufacturing protocols enriching T(SCM) CAR T cells can overcome disease-specific T cell defects in cancer patients","volume":"11","author":"Arcangeli","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.phrs.2023.106742_bib48","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nm.4441","article-title":"CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy","volume":"24","author":"Fry","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.phrs.2023.106742_bib49","doi-asserted-by":"crossref","first-page":"105741","DOI":"10.1016\/j.phrs.2021.105741","article-title":"Non-cytomembrane PD-L1: An atypical target for cancer","volume":"170","author":"Ying","year":"2021","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.phrs.2023.106742_bib50","first-page":"12","article-title":"Biomarkers for chimeric antigen receptor T cell therapy in acute lymphoblastic leukemia: prospects for personalized management and prognostic prediction","author":"Hong","year":"2021","journal-title":"Front. Immunol."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661823000981?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661823000981?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:44:08Z","timestamp":1760913848000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661823000981"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":50,"alternative-id":["S1043661823000981"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2023.106742","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Late relapse after CAR-T cell therapy for adult patients with hematologic malignancies: A definite evidence from systematic review and meta-analysis on individual data","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2023.106742","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"106742"}}